首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Cancer journal

缩写:CANCER J

ISSN:1528-9117

e-ISSN:1540-336X

IF/分区:2.1/Q3

文章目录 更多期刊信息

共收录本刊相关文章索引1187条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Rajal Sharma,Katerina Politi Rajal Sharma
Treatments for lung cancer have advanced significantly over the last 2 decades, improving survival and long-term outcomes. However, lung cancer mortality remains high, and cures for metastatic disease have remained elusive. Here, we outline...
Benjamin Y Lu,Sarah B Goldberg Benjamin Y Lu
Brain metastases are a common complication among patients with non-small cell lung cancer and are historically associated with significant morbidity and limited survival. Although surgery and radiation therapy remain essential pillars in th...
Mohammed Mohammed,Neal S McCall,Kristin A Higgins Mohammed Mohammed
Unresectable, locally advanced nonsmall cell lung cancer (LA‑NSCLC) accounts for ∼20% to 30% of newly diagnosed cases of NSCLC and remains associated with poor long‑term outcomes. Concurrent chemoradiotherapy (cCRT) has long been the the...
So Yeon Kim,Gavitt Woodard So Yeon Kim
Neoadjuvant and perioperative chemoimmunotherapy has transformed the treatment of tumors >4 cm or node-positive disease (stage II to IIIA, AJCC 8th edition) in non-small cell lung cancer (NSCLC). Compared with neoadjuvant chemotherapy alone...
Humberto E Trejo Bittar,Sanja E Dacic Humberto E Trejo Bittar
Testing for predictive biomarkers in lung cancer has evolved to integrate immunohistochemistry, tissue-based next-generation sequencing (NGS), and liquid biopsy. Tissue-based NGS remains the foundation for comprehensive genomic profiling, e...
Daniel Boiarsky,Natalie Vokes Daniel Boiarsky
The introduction of immune checkpoint inhibitors targeting the programmed death-1 (PD-1) axis represented a major therapeutic advance, enabling long-term survival, and even cure, in a subset of patients, an outcome previously considered una...
Yunan Nie,Frederick H Wilson Yunan Nie
Oncogenic gene fusions define a clinically important subset of non-small cell lung carcinoma (NSCLC) for which targeted therapies have transformed outcomes. Over the past 15 years, successive generations of tyrosine kinase inhibitors (and m...
Tämer El Saadany,Núria Aeschlimann,Adrian Sacher Tämer El Saadany
KRAS driver mutations have classically been considered undruggable by direct inhibitors in non-small cell lung cancer (NSCLC) as well as other solid tumors. However, recent advances have led to the first successful direct KRAS inhibitors, b...
Amin H Nassar,Jad Halawi,Roy S Herbst Amin H Nassar
Non-small-cell lung cancer (NSCLC) has seen a paradigm shift over the past quarter century driven by systematic molecular characterization, the advent of targeted therapies, the implementation of low-dose CT screening, and the integration o...